SCHEMBL2605308

SCHEMBL2605308

CC(C)(C)OC(=O)N1C2CCC1([C@H](N)c1ccccc1)CC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.40
GPR119 Q8TDV5 1/20 0.40
KDM1A O60341 1/20 0.39
SLC6A9 P48067 4/20 0.38
EPHX1 P07099 1/20 0.37
KDM4E B2RXH2 1/20 0.37
PKM P14618 1/20 0.37
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TSHR P16473 2/20 0.36
ALOX15 P16050 1/20 0.36
PRKCG P05129 1/20 0.36
PRKCB P05771 1/20 0.36
PRKCA P17252 1/20 0.36
PRKCH P24723 1/20 0.36
PRKCE Q02156 1/20 0.36
PRKCD Q05655 1/20 0.36
LMNA P02545 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3710583 1.00 ATM (0.40) ATMGPR119KDM1ASLC6A9EPHX1
SCHEMBL4188987 0.81 SLC6A9 (0.40) ATMGPR119KDM1ASLC6A9
SCHEMBL2126024 0.80 SLC6A9 (0.35) GPR119KDM1ASLC6A9EPHX1KDM4E
SCHEMBL2605338 0.79 CHRM2 (0.40) KDM1AEPHX1L3MBTL1
SCHEMBL2605299 0.79 CHRM2 (0.40) KDM1AEPHX1L3MBTL1
SCHEMBL2126165 0.78 SLC6A9 (0.39) ATMGPR119SLC6A9KDM4EPKM
SCHEMBL2126423 0.78 SLC6A9 (0.39) ATMGPR119SLC6A9KDM4EPKM
SCHEMBL2125188 0.78 SLC6A9 (0.39) ATMGPR119SLC6A9KDM4EPKM
SCHEMBL2605309 0.77 SLC6A9 (0.68) SLC6A9
SCHEMBL2124901 0.76 USP30 (0.38) SLC6A9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094995-A1 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2012-04-19 US disclosed
US-20120094995-A1 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2012-04-19 US disclosed
EP-2391628-A1 2-AZA-BICYCLOÝ2.2.1¨HEPTANE COMPOUNDS AND USES THEREOF AstraZeneca AB (SE) 2011-12-07 EP disclosed
WO-2010087762-A1 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-08-05 WO disclosed
WO-2010087762-A1 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094995-A1 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF SLC1A2, B4GALT1, SLC6A1 ATM 4420/4885GPR119 1048/4885KDM1A 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.